Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid

Summary

The pharmacokinetics, pharmacodynamics and safety of the direct factor Xa inhibitor, otamixaban, with and without concomitant acetylsalicylic acid (ASA) were investigated in healthy volunteers. The study was a double-blind, placebo-controlled 3-way crossover study. Sixty-eight male volunteers in total were randomised to otamixaban, ASA, or otamixaban with ASA. ASA (300 mg once a day) was started2 days before and continued on the day of the otamixaban 6-hour IV infusion (0.3 and 0.5 mg/kg). Pharmacokinetic and pharmacodynamic parameters (coagulation markers, platelet function tests and skin bleeding time) were determined. Drug interaction was assessed by the ratios of geometric means and 90 confidence intervals (90% CI)of the parameter estimates.

Pharmacokinetic parameters of otamixaban remain ed unchanged with ASA. Ratios of geometric means (90% CI) were for C_eoi 96.54 (91.21–102.19) and 95. 04 (90. 10–100. 24) and for AUC 98. 0 (93. 92–102. 25) and 95. 90 (92. 61–99. 31), for 0. 3 and 0. 5 mg/kg, respectively. No drug interaction was observed between otamixaban andASA on the coagulation and platelet function parameters. Neither otamixaban nor ASA had an effect on skin bleeding time; their co-administration led toa slight prolongation of skin bleeding time above the normal range without any clinically relevant bleeding. This study demonstrated that the desired effects of otamixaban and ASA, namely anticoagulation and platelet inhibition, respectively, are maintained during co-administration of both drugs.

Keywords

Acetylsalicylic acid - coagulation - factor Xa - pharmacokinetics - pharmacodynamics - otamixaban

• References

• 1 Braunwald E, Antman EM, Beasley JW. et al. ACC/ AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40: 1366-74.
• 2 Bertrand ME, Simoons ML, Fox KA. et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
• 3 Chu V, Brown K, Colussi D. et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001; 103: 309-24.
• 4 Rebello SS, Bentley RG, Morgan SR. et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol 2001; 133: 1190-8.
• 5 Paccaly AJ, Ozoux M, Frick A. et al. Pharmacokinetic/ pharmacodynamic relationships for factor-Xa inhibitor XRP0673 in early drug development. AAPS PharmSci. 2002 04. (Abstract W5241).
• 6 Steinijans VW, Hartmann M, Huber R. et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharm Ther Toxicol 1991; 29: 323-8.
• 7 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
• 8 Dyke CK, Becker RC, Kleiman NS. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation. Circ 2002; 105: 2382-8.
• 9 Alexander JH, Dyke CK, Yang H. et al. The XaNADU-PCI PILOT Investigators. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004; 02: 234-41.
• 10 Alexander JH, Dyke CK, Yang H. et al. on behalf of the XaNADU-ACS Investigators. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 2005; 03: 439-47.
• 11 Mammen EF, Comp PC, Gosselin R. et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
• 12 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.
• 13 Arruzazabala ML, Valdes S, Mas R. et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997; 36: 293-7.
• 14 Bang CJ, Riedel B, Talstad I. et al. Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans. Scand J Gastroenterol 1992; 27: 489-94.
• 15 de Boer A, Danhof M, Cohen AF. et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemost 1991; 66: 202-7.
• 16 Klinkhardt U, Breddin HK, Esslinger HU. et al. Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol 2000; 49: 337-41.
• 17 Cohen M, Théroux P, Weber S. et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-81.